

FOSUN PHARMA  
复星医药

2023



1

2

3

4

5

6



2023

1/2


2023

2/2

2023	2022
414.00	439.52
198.05	207.82
47.8%	47.3%
97.12	91.71
23.5%	
24.4%	9%
43.75	98
10.6%	
43.46	43.02

a




A



® PD-1

3 ES-SCLC MAA EMA

11 nsNSCLC NDA



[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]







HLX-10 (PD-1)  
HLX-22 (HER-2)

ADC

FS-1502 (HER-2 ADC)  
HLX-43 (PD-L1 ADC)  
HLX-42 (EGFR ADC)

XS-02 (CHK1)  
XS-03 (PLK1)  
FCN-159 (MEK1/2)  
FH2001 (FGFR/VEGFR)



(CD20)  
HLX-15 (CD38)

FKC-876 (CD19-CAR-T)  
FKC-889 (CD19-CAR-T)  
GCK-01 (CAR-NK)

XS-04



VS-S103 (GLP1 )

Tenapanor (ESRD-HD)

XH-S004



ET-26 (GABA )

Opicapone (COMT)

















FKC-288  
( CAR-T)

XH-S003 (Factor B)



13  
24





年	6	Y	
	   		 
		  	
			






Gland Pharma	CDMO	4	Cenexi
10			
Intas	4200		



5	800		5	16	GPO
					PD-1
					ES-SCLC
					PD-1










-





SCLC PD-1



2023

11.20



2023 6 r/r LBCL

CAR-T

2023


4



4




8



34







Gland  
Pharma









1

2,3

3



2022  
2023



1  
2  
3

1

2


Sisram



Sisram

100

78%





1.41

354.0 359.0


40.1

33.0





Intuitive Surgical



**Ion**

2024 3 Ion \*

Ion

Ion


Ion








6,080  $\xrightarrow{9.74\% \text{ YoY}}$  6,672




1,2

同比减亏4.21亿元




2

同比减亏3.52亿元



2022  
2023







1

2

2023

6,548 \* 8




















2023	4,411	8.47%
2023	1,302	7.75%
8.22%	C	2023





# 1/2

			/			IND	1	2	3	NDA
HLX10 <sup>1</sup>	+	+	PD-1	/		III 2022 11				
						2022 FDA/EC	2023 1			
	+ +	+	PD-1			III 2023 1				
			PD-1+VEGF							
			+HLX07	PD-1+EGFR						
			+HLX07 +	PD-1+EGFR +VEGF						
		+HLX208 <sup>#</sup>	PD-1+BRAFV600E	BRAFV600E	BRAFV600					
HLX07			EGFR							
HLX22 <sup>#</sup>										
HLX11	2		HER2			III				
HLX05	3		EGFR							
HLX02	4		HER2			FDA 2020				
FS-1502 <sup>#</sup>		-	HER2	HER2						
			HER2	HER2						
			PD-1	HER2						



			/		IND	1	2	3	NDA
HLX26	+		LAG-3+PD-1	mCRC					
	+	+							
		-	LAG-3						
HLX15			CD38						
HLX51			OX40						
HLX13			CTLA-4						
HLX53			TIGIT						
HLX60		-	GARP						
	+		GARP+PD-1						
HLX42			EGFR	/	FDA				
HLX43			PD-L1	/					
VT-101									
SurVaxM#			Survivin						
	(	T	)	-	GvHD				
			50R	INSR					
			25R	INSR					
				GLP-1					
				GLP-1					
				INSR					
HLX04-O <sup>1</sup>			VEGF		2022	2		III	
HLX14		2	RANKL						
RT002#									
GC101			COL7A1 CGT						

# 1/2

		/			IND	1	2	3	NDA		
FCN-437c		CDK4/6	2L								
			1L								
SAF-189		ALK/ROS1	ALK+								
			ROS1+								
HLX208#	-	BRAF	Erdheim-Chester	ECD	LCH	2023	4	LCH	ECD	NMPA	
		BRAF+PD-1	BRAFV600E	BRAFV600							
FCN-159		MEK1/2	I			2023	7	NMPA		II	
							2023	4	NMPA		
YP01001		VEGFR									
FCN-338	+	BCL-2									
	-										
	-		B								
FH-2001		FGFR/VEGFR									
XS-03		PLK1	RAS								

# 2/2

		/			IND	1	2	3	NDA
	#	TPO-R	ITP						
Tenapanor #		NHE3	CKD						
Tenapanor #		NHE3	(IBS-C)		I				
Pretomanid #		-	XDR-TB /	MDR-TB					Pretomanid*
OP0595(Nacubactam) # +		-							
Opicapone #		COMT			Ongentys*				
Fortacin #		-			*				
ET-26		-			2023 10		III		
FCN-159		MEK1/2							
SZEY-2108		-	CRE		2023 6	NMPA			
XH-S002		FXIa							
FCN-016		ROCK			2023 1	NMPA			
XH-S003		Factor B	IgA		I		2024 3	I	

			IND	1	2	3	NDA





/

T



CHO












/ /

VERO

/

mRNA





# 1/2

4+7		5mg	3
		10mg	1
		250mg	3
		150mg	3
		2.5mg	3
		100mg	4
		40mg	2
		100mg	3
		1mg/2mg	3
		250mg	2
		10mg	3
		40mg	5
	2	10mg	4
	1	500mg	1
	200mg	2	
	20mg	5	
	250mg	1	

# 2/2

50mg

10ml/3ml

3ml

1g/0.25g/0.5g/2g

0.25g/0.5g/1g

5ml/10ml/20ml

150mg

Fosun Pharma, the Representor of the P.000010733.68 20d/P 4MCID 17/Lang (en-US) BDC 0.00



[www.fosunpharma.com](http://www.fosunpharma.com)